Literature DB >> 7468501

Hemodynamic effects of intravenous prenalterol in severe heart failure.

P C Kirlin, B Pitt.   

Abstract

Nine patients with chronic severe low output heart failure (radionuclide left ventricular ejection fraction 17 +/- 5 percent [mean +/- standard deviation], left ventricular filling pressure 26 +/- 6 mm Hg, cardiac index 1.9 +/- 0.4 liters/min per m2, left ventricular stroke work index 18 +/- 6 g-m/m2) from various causes were treated with intravenous prenalterol (a new catecholamine-like inotropic agent) in doses of 1,4 and 8 mg. Significant hemodynamic improvement occurred as measured by increased left ventricular ejection fraction (to 26 +/- 4 percent), decreased left ventricular filling pressure (to 21 +/- 8 mm Hg) and increased cardiac index (to 2.4 +/- 0.6 liters/min per m2) and left ventricular stroke work index (to 25 +/- 8 g-m/m2). Significant increases in heart rate (from 87 +/- 18 to 91 +/- 18 beats/min) and mean systemic arterial pressure (from 87 +/- 8 to 92 +/- 7 mm Hg) also occurred. Peak hemodynamic response occurred at various doses. Significant adverse effects associated with prenalterol consisted of increased ventricular ectopic beats in two patients and asymptomatic ventricular tachycardia in two patients. Thus, intravenous prenalterol produces hemodynamic improvement in patients with a chronic severe low output state but may be associated with increased ventricular ectopic activity.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7468501     DOI: 10.1016/0002-9149(81)90553-1

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  11 in total

1.  The search of an ideal oral positive inotropic agent.

Authors:  L B Tan
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

2.  Effects of xamoterol a new beta-adrenoceptor partial agonist, in patients with angina pectoris.

Authors:  L Barrios; J Geboers; J H Piessens; H de Geest
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

3.  Vasodilators in heart failure.

Authors:  A Breckenridge
Journal:  Br Med J (Clin Res Ed)       Date:  1982-03-13

Review 4.  The treatment of heart failure. A methodological review of the literature.

Authors:  G H Guyatt
Journal:  Drugs       Date:  1986-12       Impact factor: 9.546

5.  Pharmacokinetics and plasma-concentration-effect relationships of prenalterol in cardiac failure.

Authors:  E J Sainsbury; D Fitzpatrick; H Ikram; M G Nicholls; E A Espiner; J J Ashley
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

6.  Cardiovascular effects of prenalterol on rest and exercise haemodynamics in patients with chronic congestive cardiac failure.

Authors:  A C Tweddel; R G Murray; D Pearson; W Martin; I Hutton
Journal:  Br Heart J       Date:  1982-04

7.  Acute intravenous and sustained oral treatment with the beta1 agonist prenalterol in patients with chronic severe cardiac failure.

Authors:  P J Currie; M J Kelly; K Middlebrook; J Federman; E Sainsbury; J Ashley; A Pitt
Journal:  Br Heart J       Date:  1984-05

8.  Acute haemodynamic effects of oral prenalterol in severe heart failure.

Authors:  M C Petch; C Wisbey; O Ormerod; C Scott; R M Goodfellow
Journal:  Br Heart J       Date:  1984-07

9.  Haemodynamic effects of ICI 118,587 in cardiomyopathy.

Authors:  S Simonsen
Journal:  Br Heart J       Date:  1984-06

10.  Prognosis and treatment of cardiomyopathy and myocarditis.

Authors:  J B O'Connell; M R Costanzo-Nordin; R S Engelmeier; D E Wallis; J A Robinson; P J Scanlon
Journal:  Heart Vessels Suppl       Date:  1985
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.